Completed Clinical Trials

 

ACE- 031 Acceleron Pharma, Inc.

Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

 

Canadian Sites:

1) Alberta Children's Hospital - Calgary, AB

2) BC Chidlren's Hospital - Vancouver, BC
3) McMaster Children's Hospital - Hamilton, ON

4) Children's Hospital -London Health Sciences Centre  - London, ON

5) Children's Hospital of Eastern Ottawa - Ottawa, ON

 

For more information visit the clinical trials website below:

https://clinicaltrials.gov/ct2/show/study/NCT01099761?term=ace-031+dmd&rank=1

 

ACE-031 Acceleron Pharma Inc.

Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

 

Canadian sites:

1) Alberta Children's Hospital - Calgary, AB

2) McMaster Children's Hospital - Hamilton, ON

3) Children's Hospital -London Health Sciences Centre  - London, ON

4) Children's Hospital of Eastern Ottawa - Ottawa, ON

 

For more information visit the clinical trials website below:

https://clinicaltrials.gov/ct2/show/study/NCT01239758?term=ace-031+dmd&rank=2

 

 

Drisapersen - GlaxoSmithKline - Completed

A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD114044)

 

Canadian Sites:

1) BC Children's Hospital - Vancouver, BC

2) Children's Hospital - London Health Sciences Centre - London, ON

3) CHU Ste- Justine - Montreal, QC

 

For  more information visit the clinical trials website below:

https://clinicaltrials.gov/ct2/show/study/NCT01254019?term=dmd114044&rank=1&show_locs=Y#locn

 

 

Drisapersen - GlaxoSmithKline - Completed

Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy

 

Canadian Sites:

1) BC Children's Hospital - Vancouver, BC

2) Children's Hospital - London Health Sciences Centre - London, ON

3) CHU Ste- Justine - Montreal, QC

 

For  more information visit the clinical trials website below:

https://clinicaltrials.gov/ct2/show/study/NCT01480245?term=GSK+drisapersen&rank=3&show_locs=Y#locn

​

Drisapersen - BioMarin- Completed

A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects

 

Candian Sites

1)  BC Children's Hospital - Vancouver, BC

2)  Children's Hospital- London Health Sciences Centre - London, ON

3)  Hôpital Ste. Justine - Montreal, QC

 

For more information visit the clinical trials website below:

​

PF-06252616 - Pfizer - Completed

An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy

 

Candian Sites

1)  Alberta Children's Hospital- Calgary, AB

2)  BC Children's Hospital - Vancouver, BC

3)  Children's Hospital- London Health Sciences Centre - London, ON

4)  Hôpital Ste. Justine - Montreal, QC

 

For more information visit the clinical trials website below:

https://clinicaltrials.gov/ct2/show/study/NCT02907619?cond=dmd&cntry=CA&show_locs=Y

​

PF-06252616 - Pfizer -  Completed

A Phase 2 Randomized, Double-Blind, Placebo‑Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Ambulatory Boys with Duchenne Muscular Dystrophy

 

Candian Sites

1)  Alberta Children's Hospital- Calgary, AB

2)  BC Children's Hospital - Vancouver, BC

3)  Children's Hospital- London Health Sciences Centre - London, ON

4)  Hôpital Ste. Justine - Montreal, QC

 

For more information visit the clinical trials website below:

https://clinicaltrials.gov/ct2/show/NCT02310763?term=PF-06252616&rank=2

​

SMNRx- ISIS -  Completed

A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Later-onset Spinal Muscular Atrophy

 

Canadian sites

1)   Children's Hospital- London Health Sciences Centre - London, ON

2)  The Research Institute of the McGill University Health Centre

- Montreal,  QC

 

For more information and participant eligibility visit the clinical trial site below:

​https://clinicaltrials.gov/ct2/show/NCT02292537?term=SMA+ISIS&rank=5

 

 

SMNRx- ISIS - Completed

A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Infantile-onset Spinal Muscular Atrophy

 

Canadian sites:

1)   Hospital for Sick Children - Toronto, ON

2)  The Research Institut of the McGill University Health Centre

- Montreal,  QC

3)   British Columbia's Children's Hospital- Vancouver, BC

 

For more information and participant eligibility visit the clinical trial site below:

https://clinicaltrials.gov/ct2/show/study/NCT02193074?term=SMA+ISIS&rank=4&show_locs=Y#locn